These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 20016672)
41. Antibiotic Susceptibility Patterns of Mycobacterium tuberculosis Isolates from Guizhou Province of China Against 13 Antituberculosis Drugs. Li N; Liao X; Chen L; Wang J; Liu M; Zhang H Microb Drug Resist; 2015 Jun; 21(3):292-6. PubMed ID: 25599413 [TBL] [Abstract][Full Text] [Related]
42. Prevalence and molecular characterization of amikacin resistance among Mycobacterium tuberculosis clinical isolates from southern China. Islam MM; Tan Y; Hameed HMA; Liu Y; Chhotaray C; Cai X; Liu Z; Lu Z; Wang S; Cai X; Su B; Li X; Tan S; Liu J; Zhang T J Glob Antimicrob Resist; 2020 Sep; 22():290-295. PubMed ID: 32142951 [TBL] [Abstract][Full Text] [Related]
43. Overview of anti-tuberculosis (TB) drugs and their resistance mechanisms. Shi R; Itagaki N; Sugawara I Mini Rev Med Chem; 2007 Nov; 7(11):1177-85. PubMed ID: 18045221 [TBL] [Abstract][Full Text] [Related]
44. Prevalence and detection of drug resistant mutations in Mycobacterium tuberculosis among drug naïve patients in Nairobi, Kenya. Ogari CO; Nyamache AK; Nonoh J; Amukoye E BMC Infect Dis; 2019 Mar; 19(1):279. PubMed ID: 30909867 [TBL] [Abstract][Full Text] [Related]
45. Identification of gene targets against dormant phase Mycobacterium tuberculosis infections. Murphy DJ; Brown JR BMC Infect Dis; 2007 Jul; 7():84. PubMed ID: 17655757 [TBL] [Abstract][Full Text] [Related]
46. PE_PGRS: Vital proteins in promoting mycobacterial survival and modulating host immunity and metabolism. Xie Y; Zhou Y; Liu S; Zhang XL Cell Microbiol; 2021 Mar; 23(3):e13290. PubMed ID: 33217152 [TBL] [Abstract][Full Text] [Related]
47. Tetany in an Extensively Drug Resistant Tuberculosis (XDR-TB) Patient Treated with Capreomycin. Puri MM; Kumar A; Aneja P; Gupta R; Kumar L; Sarin R J Assoc Physicians India; 2019 Aug; 67(8):79-82. PubMed ID: 31562727 [TBL] [Abstract][Full Text] [Related]
48. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Maus CE; Plikaytis BB; Shinnick TM Antimicrob Agents Chemother; 2005 Aug; 49(8):3192-7. PubMed ID: 16048924 [TBL] [Abstract][Full Text] [Related]
49. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Feuerriegel S; Cox HS; Zarkua N; Karimovich HA; Braker K; Rüsch-Gerdes S; Niemann S Antimicrob Agents Chemother; 2009 Aug; 53(8):3353-6. PubMed ID: 19470506 [TBL] [Abstract][Full Text] [Related]
50. Phylogeny to function: PE/PPE protein evolution and impact on Mycobacterium tuberculosis pathogenicity. Fishbein S; van Wyk N; Warren RM; Sampson SL Mol Microbiol; 2015 Jun; 96(5):901-16. PubMed ID: 25727695 [TBL] [Abstract][Full Text] [Related]
51. [Evolution of IGRA researches]. Ariga H; Harada N Kekkaku; 2008 Sep; 83(9):641-52. PubMed ID: 18979999 [TBL] [Abstract][Full Text] [Related]
52. [Investigation of extensive drug resistance in multidrug resistance tuberculosis isolates]. Bektöre B; Haznedaroğlu T; Baylan O; Ozyurt M; Ozkütük N; Satana D; Cavuşoğlu C; Seber E Mikrobiyol Bul; 2013 Jan; 47(1):59-70. PubMed ID: 23390903 [TBL] [Abstract][Full Text] [Related]
53. [Action and resistance mechanisms of capreomycin: a functional genomic perspective]. Liu XM; Xie JP Yao Xue Xue Bao; 2008 Aug; 43(8):788-92. PubMed ID: 18956769 [TBL] [Abstract][Full Text] [Related]
54. Comparisons of whole-genome sequencing and phenotypic drug susceptibility testing for Mycobacterium tuberculosis causing MDR-TB and XDR-TB in Thailand. Faksri K; Kaewprasert O; Ong RT; Suriyaphol P; Prammananan T; Teo YY; Srilohasin P; Chaiprasert A Int J Antimicrob Agents; 2019 Aug; 54(2):109-116. PubMed ID: 30981926 [TBL] [Abstract][Full Text] [Related]
55. [Screening and analysis of in vivo induced genes of Mycobacterium tuberculosis]. Zhang ZD; Li ZH; DU BP; Jia HY; Liu ZQ; Chen X; Huang HR; Xing AY; Gu SX; Ma Y Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(3):189-93. PubMed ID: 18361819 [TBL] [Abstract][Full Text] [Related]
56. Transcriptional profile of Mycobacterium tuberculosis replicating in type II alveolar epithelial cells. Ryndak MB; Singh KK; Peng Z; Laal S PLoS One; 2015; 10(4):e0123745. PubMed ID: 25844539 [TBL] [Abstract][Full Text] [Related]
57. Evaluation of the microscopic observation drug susceptibility assay for the rapid detection of MDR-TB and XDR-TB in China: a prospective multicentre study. Huang Z; Qin C; Du J; Luo Q; Wang Y; Zhang W; Zhang X; Xiong G; Chen J; Xu X; Li W; Li J J Antimicrob Chemother; 2015 Feb; 70(2):456-62. PubMed ID: 25266071 [TBL] [Abstract][Full Text] [Related]
58. Comparative Genomics and Proteomic Analysis of Four Non-tuberculous Mycobacterium Species and Mycobacterium tuberculosis Complex: Occurrence of Shared Immunogenic Proteins. Gcebe N; Michel A; Gey van Pittius NC; Rutten V Front Microbiol; 2016; 7():795. PubMed ID: 27375559 [TBL] [Abstract][Full Text] [Related]
59. Molecular analysis of genetic mutations among cross-resistant second-line injectable drugs reveals a new resistant mutation in Mycobacterium tuberculosis. Malinga L; Brand J; Olorunju S; Stoltz A; van der Walt M Diagn Microbiol Infect Dis; 2016 Aug; 85(4):433-7. PubMed ID: 27298046 [TBL] [Abstract][Full Text] [Related]
60. Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions. Gey van Pittius NC; Sampson SL; Lee H; Kim Y; van Helden PD; Warren RM BMC Evol Biol; 2006 Nov; 6():95. PubMed ID: 17105670 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]